Intersect ENT Inc. (NASDAQ:XENT) saw strong trading volume on Monday . 962,407 shares traded hands during trading, an increase of 156% from the previous session’s volume of 375,339 shares.The stock last traded at $15.27 and had previously closed at $13.82.

Several equities research analysts recently commented on the company. Zacks Investment Research cut Intersect ENT from a “hold” rating to a “sell” rating in a research report on Wednesday, April 27th. Cantor Fitzgerald reissued a “buy” rating and issued a $29.00 target price on shares of Intersect ENT in a research report on Thursday, March 24th. Northland Securities initiated coverage on Intersect ENT in a research report on Tuesday, March 29th. They issued an “outperform” rating and a $26.00 target price on the stock. Leerink Swann reissued a “buy” rating on shares of Intersect ENT in a research report on Thursday, March 24th. Finally, Canaccord Genuity reissued a “buy” rating on shares of Intersect ENT in a research report on Thursday, March 24th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $26.33.

The firm’s 50-day moving average price is $13.62 and its 200-day moving average price is $16.58. The company’s market cap is $432.25 million.

Intersect ENT (NASDAQ:XENT) last issued its earnings results on Thursday, May 5th. The company reported ($0.29) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.29). The firm earned $16.69 million during the quarter, compared to the consensus estimate of $16.92 million. During the same period in the previous year, the company posted ($0.23) EPS. The firm’s revenue for the quarter was up 24.8% on a year-over-year basis. Equities analysts predict that Intersect ENT Inc. will post ($1.01) earnings per share for the current year.

In other news, Director Kieran Gallahue bought 8,000 shares of the stock in a transaction on Monday, May 16th. The stock was purchased at an average price of $12.64 per share, with a total value of $101,120.00. Following the completion of the purchase, the director now owns 8,000 shares of the company’s stock, valued at $101,120. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Richard E. Kaufman sold 3,603 shares of the company’s stock in a transaction that occurred on Wednesday, April 20th. The shares were sold at an average price of $18.86, for a total transaction of $67,952.58. Following the completion of the transaction, the chief operating officer now owns 198,174 shares of the company’s stock, valued at approximately $3,737,561.64. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently added to or reduced their stakes in the stock. Gratus Capital LLC boosted its position in Intersect ENT by 5.3% in the fourth quarter. Gratus Capital LLC now owns 68,091 shares of the company’s stock valued at $1,532,000 after buying an additional 3,440 shares during the period. Mutual of America Capital Management LLC boosted its position in Intersect ENT by 77.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 92,311 shares of the company’s stock valued at $2,077,000 after buying an additional 40,311 shares during the period. Nationwide Fund Advisors boosted its position in Intersect ENT by 95.2% in the fourth quarter. Nationwide Fund Advisors now owns 198,487 shares of the company’s stock valued at $4,466,000 after buying an additional 96,794 shares during the period. Tamarack Advisers LP bought a new position in Intersect ENT during the fourth quarter valued at $5,609,000. Finally, Schroder Investment Management Group bought a new position in Intersect ENT during the fourth quarter valued at $6,845,000.

Intersect ENT, Inc is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.